154 related articles for article (PubMed ID: 19859691)
1. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.
Simon D
Diabetologia; 2010 Jan; 53(1):204-5. PubMed ID: 19859691
[No Abstract] [Full Text] [Related]
2. Insulin glargine and incidence of cancer--an ongoing debate.
Hermanns N; Kulzer B
J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
[No Abstract] [Full Text] [Related]
3. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
Butler PC
Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
[No Abstract] [Full Text] [Related]
4. Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.
Nagel JM; Mansmann U; Wegscheider K; Röhmel J
Diabetologia; 2010 Jan; 53(1):206-8. PubMed ID: 19774358
[No Abstract] [Full Text] [Related]
5. [Increased risk of cancer using insulin and insulin analogues?].
Schäffler A
MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
[No Abstract] [Full Text] [Related]
6. Risk of cancer in patients receiving insulin glargine.
Dawson LK; Hamilton LA
Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
[TBL] [Abstract][Full Text] [Related]
7. Editorial: glargine, a new long-acting insulin analog for diabetic cats.
Rand J
J Vet Intern Med; 2006; 20(2):219-20. PubMed ID: 16594574
[No Abstract] [Full Text] [Related]
8. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
9. Insulin glargine and malignancy: an unwarranted alarm.
Pocock SJ; Smeeth L
Lancet; 2009 Aug; 374(9689):511-3. PubMed ID: 19616841
[No Abstract] [Full Text] [Related]
10. A possible link between insulin glargine and malignancy: the facts.
Mollentze WF
Cardiovasc J Afr; 2009; 20(4):216-8; discussion 218-9. PubMed ID: 19701528
[No Abstract] [Full Text] [Related]
11. Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes.
Rosenstock J; Owens D
Expert Opin Pharmacother; 2004 Jan; 5(1):1-2; author reply 2-3. PubMed ID: 14680430
[No Abstract] [Full Text] [Related]
12. Mitogenic action of insulin: friend, foe or 'frenemy'?
Draznin B
Diabetologia; 2010 Feb; 53(2):229-33. PubMed ID: 19851749
[TBL] [Abstract][Full Text] [Related]
13. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine and cancer--an unsubstantiated allegation.
Garg SK; Hirsch IB; Skyler JS
Diabetes Technol Ther; 2009 Aug; 11(8):473-6. PubMed ID: 19591544
[No Abstract] [Full Text] [Related]
15. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1971-3. PubMed ID: 19609501
[No Abstract] [Full Text] [Related]
16. Diabetic retinopathy and insulin glargine.
Chantelau E
Diabetologia; 2009 Oct; 52(10):2233; author reply 2236-9. PubMed ID: 19680626
[No Abstract] [Full Text] [Related]
17. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.
Karlstad O; Starup-Linde J; Vestergaard P; Hjellvik V; Bazelier MT; Schmidt MK; Andersen M; Auvinen A; Haukka J; Furu K; de Vries F; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):333-48. PubMed ID: 24215311
[TBL] [Abstract][Full Text] [Related]
18. [Insulin glargine and cancer: a storm in a glass of water?].
Scheen AJ; Lefebvre PJ
Rev Med Liege; 2009 Sep; 64(9):440-5. PubMed ID: 19947313
[TBL] [Abstract][Full Text] [Related]
19. Insufficient evaluation of adverse events is not a proof of safety.
Hemkens LG; Grouven U; Bender R; Sawicki PT
Diabetologia; 2010 Apr; 53(4):790-2; author reply 793-4. PubMed ID: 20099058
[No Abstract] [Full Text] [Related]
20. Dualities of interest are not restricted to financial ties to the pharmaceutical industry.
Nauck M
Diabetologia; 2010 Jan; 53(1):212-3. PubMed ID: 19921143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
